A Phase 1 interventional study of XY0206 in Advanced or Metastatic Solid Tumours, sponsored by Shijiazhuang Yiling Pharmaceutical Co. Ltd. Status unknown at 4 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-08-21.
Sponsored by Shijiazhuang Yiling Pharmaceutical Co. Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Shijiazhuang Yiling Pharmaceutical Co. Ltd is the lead sponsor of 13 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must meet all of the following criteria before entering the group:
Exclusion Criteria:
Patients cannot participate in this clinical study if they meet any of the following conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug:XY0206;Dosage form:Tablet;Dosage:12.5mg;Include single dose treatment and multiple dose phase
Drug: XY0206
Drug:XY0206;Dosage form:Tablet;Dosage:25mg;Include single dose treatment and multiple dose phase
Drug: XY0206
Drug:XY0206;Dosage form:Tablet;Dosage:37.5mg;Include single dose treatment and multiple dose phase
Drug: XY0206
Drug:XY0206;Dosage form:Tablet;Dosage:50mg;Include single dose treatment and multiple dose phase
Drug: XY0206
Drug:XY0206;Dosage form:Tablet;Dosage:75mg;Include single dose treatment and multiple dose phase
Drug: XY0206
Drug:XY0206;Dosage form:Tablet;Dosage:100mg;Include single dose treatment and multiple dose phase
Drug: XY0206
Dosage form:Tablet;Single dose treatment:Take the drug once on day 1,each time 1 tablet. Multiple dose phase:Take the medicine once a day,1 tablet at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until they meet the criteria for stopping treatment or determine the duration and interval of treatment according to the accumulated condition after multiple dose.
DLT
The occurrence of DLT.
Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication
AE
The occurrence rate of AE.
Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication
ADR
The occurrence rate of adverse drug reactions(ADR).
Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication
SAE
The occurrence rate of SAE.
Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication
Blood routine
One of the laboratory tests.
Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication
Urine routine
One of the laboratory tests.
Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication
Stool routine
One of the laboratory tests.
Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication
Blood biochemistry
One of the laboratory tests.
Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication
Coagulation function
One of the laboratory tests.
Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication
12 lead ecg
One of the laboratory tests.
Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication
Body temperature
One of the vital signs.
Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication
Blood pressure
One of the vital signs.
Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication
Heart rate
One of the vital signs.
Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication
Breathing
One of the vital signs.
Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication
General condition
One of the physical examination.
Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication
Skin
One of the physical examination.
Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication
Head
One of the physical examination.
Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication
Eyes
One of the physical examination.
Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication
Ears
One of the physical examination.
Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication
Nose
One of the physical examination.
Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication
Throat
One of the physical examination.
Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication
Heart
One of the physical examination.
Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication
Lung
One of the physical examination.
Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication
Chest
One of the physical examination.
Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication
Abdomen
One of the physical examination.
Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication
Limbs
One of the physical examination.
Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication
Nerves
One of the physical examination.
Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication
Back/spine
One of the physical examination.
Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication
Lymph nodes
One of the physical examination.
Time frame: from the start of the medication to the end of the study or 28 days after cessation of medication
AUCinf
area under the concentration-time curve from the time of dosing extrapolated to time infinity.
Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours
AUC0-24h
area under the concentration-time curve from the time of dosing extrapolated to the 24h after dosing.
Time frame: single dose phase:up to 24 hours;multiple dose phase:up to 24 hours
AUC0-72h
area under the concentration-time curve from the time of dosing extrapolated to the 72h after dosing.
Time frame: single dose phase:up to 72 hours
AUC0-120h
area under the concentration-time curve from the time of dosing extrapolated to the 120h after dosing.
Time frame: single dose phase:up to 120 hours
Peak Plasma Concentration (Cmax)
The PK parameters of the plasma sample.
Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours
CL/F
The PK parameters of the plasma sample.
Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours
Tmax
The amount of time that a drug is present at the maximum concentration in serum.
Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours
Cmin,ss
The PK parameters of the plasma sample.
Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours
Cmax,ss
The PK parameters of the plasma sample.
Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours
Cav,ss
The PK parameters of the plasma sample.
Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours
PTF
The PK parameters of the plasma sample.
Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours
RAUC1
The PK parameters of the plasma sample.
Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours
RAUC2
The PK parameters of the plasma sample.
Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours
RCmax
The PK parameters of the plasma sample.
Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours
Kel
The PK parameters of the plasma sample.
Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours
t1/2
The PK parameters of the plasma sample.
Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours
Vz/F
The PK parameters of the plasma sample.
Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours
AUC_%Extrap
The PK parameters of the plasma sample.
Time frame: single dose phase:up to 120 hours;multiple dose phase:up to 24 hours
Ae0-24h
The PK parameters of the plasma sample.
Time frame: single dose phase:up to 24 hours;multiple dose phase:up to 24 hours
Fe0-24h
The PK parameters of the plasma sample.
Time frame: single dose phase:up to 24 hours;multiple dose phase:up to 24 hours
Ae0-72h
The PK parameters of the plasma sample.
Time frame: single dose phase:up to 72 hours
Fe0-72h
The PK parameters of the plasma sample.
Time frame: single dose phase:up to 72 hours
Ae0-72h stool
The PK parameters of the plasma sample.
Time frame: single dose phase:up to 72 hours
CLr
The PK parameters of the plasma sample.
Time frame: single dose phase:up to 24 hours;multiple dose phase:up to 24 hours
Exploring the relative baseline change percentage of biomarkers (soluble VEGFR2).
The PD parameters of XY0206.
Time frame: single dose phase:up to 24 hours;multiple dose phase:up to 24 hours
Complete response rate (CRR)
Effective parameters of XY0206.
Time frame: through study completion,such as 30 months.
Partial response rate (PRR)
Effective parameters of XY0206.
Time frame: through study completion,such as 30 months.
Objective response rate (ORR)
Effective parameters of XY0206.
Time frame: through study completion,such as 30 months.
Progression-free survival (PFS)
Effective parameters of XY0206.
Time frame: through study completion,such as 30 months.
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2018 (actual). Primary completion is estimated for Dec 2020, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: FLT3 Inhibitor XY0206
Shijiazhuang Yiling Pharmaceutical Co. Ltd